Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes
Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes
Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic.
安大略省多倫多-(Newsfile Corp.-2022年6月30日)-Aion治療公司(CSE：AION) ("Aion治療“或”公司“)今天宣佈，已向Apollon Formary PLC出售了四項專利申請和所有相關的支持數據(”阿波龍)，一家在Aquis證券交易所上市的英國國際製藥公司。此外，史蒂芬·D·巴恩希爾博士已經辭去艾昂治療公司首席科學官一職，赫伯特·弗裏策爾博士已經辭去艾昂治療公司首席科學官一職。
Under the terms of an asset purchase agreement (the "APA"), the Company has sold four patent applications, and all associated supporting data to Apollon (collectively, the "Intellectual Property") as detailed below:
根據資產購買協議的條款(“APA)，公司已向Apollon出售了四項專利申請和所有相關的支持數據(合計為知識產權“)詳情如下：
- Compositions and Methods for Treatment of Cancers;
- Compositions and Methods for Treatment of Inflammation;
- Methods for Treatment of Human Cancers Using Mushroom Compositions; and
- Methods for Treatment of Human Cancers Using Cannabis Compositions.
- 治療癌症的組合物和方法；
- 治療炎症的組合物和方法；
- 使用蘑菇組合物治療人類癌症的方法；以及
- 使用大麻組合物治療人類癌症的方法。
In consideration for the Intellectual Property, Apollon has (i) issued to Aion Therapeutic an aggregate of 4,348,679 common shares of Apollon at a deemed price of £0.066 per share; and (ii) agreed to pay to Aion Therapeutic an indefinite royalty fee of 4% of the global net revenue generated by the Intellectual Property (the "Royalty"). The Royalty is payable quarterly in arrears, commencing upon the first commercial product sales utilizing the Intellectual Property.
作為知識產權的代價，Apollon已(I)按每股0.066 GB的價格向Aion治療公司發行了總計4,348,679股Apollon普通股；以及(Ii)同意向Aion治療公司支付相當於該知識產權產生的全球淨收入4%的無限期使用費。版税“)。特許權使用費從第一次使用知識產權的商業產品銷售開始，每季度支付一次。
The Company has retained the following patent applications:
公司保留了以下專利申請：
- Compositions and Methods for Treatment of Psychoses and Psychotic Disorders;
- Compositions and Methods for Promoting Weight Loss and for Treatment of Obesity;
- Antiviral Compositions and Methods for Their Use;
- Compositions For Treatment of Interstitial Cystitis and Other Bladder Disease;
- Cannabis Compositions and Emulsions; and
- Cannabis Compositions and Nanoemulsions.
- 治療精神病和精神障礙的組合物和方法；
- 促進減肥和治療肥胖的組合物和方法；
- 抗病毒組合物及其使用方法；
- 治療間質性膀胱炎和其他膀胱疾病的組合物；
- 大麻組合物和乳劑；以及
- 大麻組合物和納米乳劑。
Graham Simmonds, Chief Executive Officer of Aion Therapeutic, stated, "The Company has sold its intellectual property to Apollon associated with the treatment of cancer and inflammation which will allow Aion Therapeutic to focus on product development and intellectual property development related to a range of innovative plant-based wellness products including cannabinoids and functional mushrooms in Jamaica and North America. Aion Therapeutic also continues to be a long-term believer in the potential of psilocybin mushrooms and other psychedelic ingredients in the areas of mental health and wellness treatments and will leverage the regulatory landscape and its presence in Jamaica to drive forward operation of Aion International Center for Psychedelic Psychiatry."
Aion治療公司首席執行官格雷厄姆·西蒙茲表示：“公司已將其與癌症和炎症治療相關的知識產權出售給Apollon，這將使Aion治療公司能夠專注於產品開發和與牙買加和北美的一系列創新植物保健產品相關的知識產權開發，包括大麻素和功能性蘑菇。Aion治療公司還繼續長期相信裸蓋菇素蘑菇和其他迷幻成分在心理健康和健康治療領域的潛力，並將利用監管格局和其在牙買加的存在來推動Aion國際迷幻精神病學中心的運營。”
This repositioning of the Company's assets will provide for a more streamlined approach to the commercialization of functional wellness-based products and treatments while still having shareholders benefiting through Royalties and stock ownership from Apollon's focus on the treatment of cancer and inflammation.
該公司資產的重新定位將為基於功能健康的產品和治療的商業化提供一種更精簡的方法，同時仍使股東從阿波隆專注於癌症和炎症治療的特許權使用費和股票所有權中受益。
The APA was unanimously approved by all disinterested directors of the Company. Dr. Barnhill is the Chairman and Chief Executive Officer of Apollon and abstained from voting to approve the APA.
APA獲得本公司所有無利害關係董事的一致通過。巴恩希爾博士是Apollon的董事長兼首席執行官，他對批准《行政程序法》投了棄權票。
Furthermore, the Company announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and from all subsidiary level appointments, and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022. The Company would like to thank Dr. Barnhill and Dr. Fritsche for their respective contributions and wish them success in their future endeavors.
此外，公司還宣佈，斯蒂芬·D·巴恩希爾博士已辭去怡安治療公司首席科學官一職，赫伯特·弗裏策爾博士已辭去怡安治療公司首席科學官一職，兩人的辭職均將於2022年6月30日生效。本公司感謝巴恩希爾博士和弗裏切爾博士分別作出的貢獻，並祝願他們在未來的工作中取得成功。
In connection with Dr. Barnhill's resignation, Aion Therapeutic has issued an aggregate of 5,500,000 common shares of the Company at a deemed price of $0.05 per share to settle all amounts owing by Aion Therapeutic and its subsidiaries to Dr. Barnhill (the "Settlement Transaction"). The common shares issued to Dr. Barnhill are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation, and such further restrictions as apply under foreign securities laws.
關於巴恩希爾博士的辭職，Aion治療公司已按每股0.05美元的價格發行了總計5,500,000股公司普通股，以清償Aion治療公司及其子公司欠巴恩希爾博士的所有金額。結算交易根據適用的證券法，向巴恩希爾博士發行的普通股的法定持有期為四個月加自發行之日起計的一天，根據外國證券法適用的此類進一步限制。
The Settlement Transaction constituted a "related party transaction" as defined in Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions ("MI 61-101"), as Dr. Barnhill was a director of Aion Therapeutic at the time of the Settlement Transaction and acquired an aggregate of 5,500,000 common shares of the Company. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a), respectively, of MI 61-101, as the fair market value of the common shares issued to Dr. Barnhill does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the transaction, which the Company deems reasonable in order to complete the Settlement Transaction in an expeditious manner. The Settlement Transaction was unanimously approved by all disinterested directors of the Company.
結算交易構成多邊文書61-101所界定的“關聯方交易”--特殊交易中少數股證券持有人的保護 ("米其林61-101“)，因為在結算交易發生時，巴恩希爾博士是怡安治療公司的董事成員，並收購了總計5,500,000股本公司的普通股。本公司依據MI 61-101第5.5(A)及5.7(1)(A)節分別載於MI 61-101的估值及少數股東批准規定的豁免，因為根據MI 61-101釐定，向巴恩希爾博士發行的普通股的公平市值不超過本公司市值的25%。本公司並無於交易結束前至少21天提交有關關聯方交易的重大變動報告，本公司認為此舉是合理的，以便迅速完成結算交易。和解交易獲得本公司全體無利害關係董事的一致通過。
About Aion Therapeutic Inc.
Aion治療公司簡介
Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.
Aion治療公司通過其全資子公司AI PharmPharmticals牙買加有限公司從事研發、治療、數據挖掘和最先進的人工智能(機器學習)技術業務，專注於在合法環境下開發組合藥品、營養食品和化粧品，利用大麻(大麻)、迷幻蘑菇(裸蓋菇素)、真菌(食用菌)、天然迷幻製劑(Ayahuasca)和其他藥用植物的化合物進行此類發現。此外，Aion治療公司正在創建與其發現相關的強大的國際知識產權組合。
For further information, please contact:
如需更多信息，請聯繫：
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
Aion治療公司
格雷厄姆·西蒙茲
執行副主席兼首席執行官
(416) 843-2881
DISCLAIMER & READER ADVISORY
免責聲明和讀者建議
Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.
本新聞稿中陳述的某些信息可能包含前瞻性信息，這些信息涉及大量已知和未知的風險和不確定性。這些前瞻性信息受到許多風險和不確定性的影響，其中某些風險和不確定性不是公司所能控制的，包括但不限於一般經濟條件、行業條件和對監管批准的依賴的影響。請讀者注意，編制這類信息時使用的假設雖然在編制時被認為是合理的，但可能被證明是不準確的，因此不應過度依賴前瞻性信息。雙方不承擔更新前瞻性信息的義務，除非適用的證券法另有要求。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。